Incannex Healthcare (IXHL) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Incannex Healthcare (IXHL) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 80.3% versus a loss of 86.6%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $20.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | RNAZ |
|---|---|---|
| Share price | $1.86 | $1.16 |
| Market cap | $23.34M | $20.07M |
| 1-day change | +6.90% | -10.77% |
| YTD return | -82.68% | -83.02% |
| 1-year return | -80.32% | -86.57% |
| 5-year return | — | -100.00% |
| EPS (TTM) | $-1.25 | $-47.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-19.30M | $-34.66M |
| 52-week high | $14.91 | $12.60 |
| 52-week low | $1.61 | $1.01 |
| Distance from 52-week high | -87.53% | -90.79% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +904.30% | — |
| Average volume | 91.61K | 52.03K |
| Shares outstanding | 12.55M | 17.30M |
| Employees | 12 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
IXHL vs RNAZ FAQ
Which is bigger, Incannex Healthcare or TransCode Therapeutics?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $20.07M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, IXHL or RNAZ?
IXHL returned -80.32% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.